Therachon, which had raised $100m from investors including Pfizer Ventures and Novo, has agreed to be acquired by Pfizer in a deal that could potentially reach $810m.

Pharmaceutical firm Pfizer agreed yesterday to acquire portfolio company Therachon, a Switzerland-based developer of treatments for rare genetic disorders, in a deal sized at $340m upfront. The upfront payment could be swelled by up to $470m in additional milestone payments related to the development of Therachon’s lead asset, TA-46, a treatment for a bone growth…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.